Technical Analysis for PFNX - Pfenex Inc.

Grade Last Price % Change Price Change
grade A 6.76 -2.17% -0.15
PFNX closed down 2.17 percent on Friday, May 17, 2019, on 31 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical PFNX trend table...

Date Alert Name Type % Chg
New Uptrend Bullish 0.00%
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Sell Signal Bearish -2.17%
Upper Bollinger Band Walk Strength -2.17%
Wide Bands Range Expansion -2.17%
Overbought Stochastic Strength -2.17%
Upper Bollinger Band Touch Strength -2.17%

Older signals for PFNX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Pfenex Inc., a clinical-stage biotechnology company, is engaged in the development of biosimilar therapeutics. Its lead product candidate includes PF582, a biosimilar candidate to Lucentis that is in Phase Ib/IIa trials in patients with wet age-related macular degeneration. The company also develops PF530, an interferon beta-1b biosimilar candidate to the Betaseron to reduce the relapses in patients with relapsing forms of multiple sclerosis; PF694, an interferon alpha-2a biosimilar candidate to the reference product Pegasys; and other biosimilar candidates. In addition, it develops PF708, a teriparatide generic peptide product candidate to the reference listed drug Forteo; Px563L, an anthrax vaccine candidate based on a recombinant modified form of the protective antigen; and Px533, a prophylactic vaccine candidate to protect against malaria infection. The company has collaboration with Strides Arcolab Limited for the development of PF530. Pfenex Inc. is headquartered in San Diego, California.
Medicine Biotechnology Life Sciences Biology Drugs Multiple Sclerosis Wet Age Related Macular Degeneration Antivirals Biosimilar Anthrax Interferon
Is PFNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 7.4
52 Week Low 3.13
Average Volume 213,063
200-Day Moving Average 4.7594
50-Day Moving Average 5.8904
20-Day Moving Average 6.021
10-Day Moving Average 6.293
Average True Range 0.4364
ADX 26.38
+DI 28.783
-DI 9.9484
Chandelier Exit (Long, 3 ATRs ) 6.0908
Chandelier Exit (Short, 3 ATRs ) 6.5592
Upper Bollinger Band 7.0349
Lower Bollinger Band 5.0071
Percent B (%b) 0.86
BandWidth 33.678791
MACD Line 0.2761
MACD Signal Line 0.1494
MACD Histogram 0.1267
Fundamentals Value
Market Cap 159.04 Million
Num Shares 23.5 Million
EPS 0.06
Price-to-Earnings (P/E) Ratio 112.67
Price-to-Sales 1.08
Price-to-Book 1.09
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.18
Resistance 3 (R3) 7.21 7.10 7.11
Resistance 2 (R2) 7.10 6.99 7.09 7.09
Resistance 1 (R1) 6.93 6.93 6.88 6.90 7.06
Pivot Point 6.82 6.82 6.79 6.81 6.82
Support 1 (S1) 6.65 6.71 6.60 6.62 6.46
Support 2 (S2) 6.54 6.65 6.53 6.43
Support 3 (S3) 6.37 6.54 6.41
Support 4 (S4) 6.34